|
|
Oculus Announces SFDA Approval of Microcyn
publication date: Mar 31, 2008
Oculus Innovative Sciences has received an approval from the SFDA of its Microcyn® Technology for treatment of several acute and chronic wounds including ulcers, cuts, contusions and burns. Microcyn is a super-oxygenated form of water that is not toxic, but highly effective against bacteria, viruses, mold and spores. Microcyn combines its anti-infective properties with the ability to promote wound healing. More details...
Stock Symbol: (NSDQ: OCLS)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Other Events
China Pharmaceutical R&D SummitApril 23-26, 2012 Shanghai, China Biosimilars Asia 2012April 23-26, 2012 Shanghai, China Vaccines China 2012April 23-26, 2012 Shanghai, China
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|